HIV-1 INCIDENCE DETERMINED RETROSPECTIVELY AMONG DRUG-USERS IN BANGKOK, THAILAND

Citation
D. Kitayaporn et al., HIV-1 INCIDENCE DETERMINED RETROSPECTIVELY AMONG DRUG-USERS IN BANGKOK, THAILAND, AIDS, 8(10), 1994, pp. 1443-1450
Citations number
54
Categorie Soggetti
Immunology,"Infectious Diseases
Journal title
AIDSACNP
ISSN journal
02699370
Volume
8
Issue
10
Year of publication
1994
Pages
1443 - 1450
Database
ISI
SICI code
0269-9370(1994)8:10<1443:HIDRAD>2.0.ZU;2-J
Abstract
Objective: To measure trends in the incidence of HIV-1 infection among drug users in treatment at Thailand's largest drug detoxification uni t. Design: A retrospective cohort was established using computed, exis ting HIV-1 test results of 26 396 inpatients and outpatients admitted for 47 907 drug detoxification treatment courses from August 1987 to A ugust 1992. Methods: Matching of patient record numbers showed that 10 050 (38.1%) patients had been admitted two or more times during the p eriod. From these, we selected a cohort of 7807 initially HIV-negative patients. Subsequent seroconversions among them were assumed to have occurred with uniform probability throughout the interval between the last HIV-negative and the first HIV-positive tests. Results: There wer e 2311 (29.6%) seroconversions in the cohort. HIV-1 incidence among th e 5974 (76.5%) who were injecting drug users (IDU) escalated from 20 n ew infections per 100 person-years (PY) of observation in 1987 to a pe ak of 57 per 100 PY in 1988, then gradually declining to a stable tate of about 11 per 100 PY during 1991 and 1999. Non-IDU (smokers, inhale rs) constituted 683 (8.8%) of the cohort patients, and had HIV-1 incid ence rates varying from 0.2 to five per 100 PY. 'Mixed' drug users, de fined as individuals reporting different routes of drug administration on different admissions, composed 1150 (14.7%) of cohort patients and had an HIV-1 incidence rate between that of IDU and non-IDU. Prevalen ce of HIV-1 seropositivity among ail IDU increased rapidly, from about 1% in early 1988 to a peak or about 40% by early 1989, and has remain ed stable through 1992. Conclusions: Prevention efforts must continue for IDU, since recent annual HIV-1 incidence remains high at >10 per 1 00 PY. Such a high rate suggests that this group should be considered for HIV-1 vaccine efficacy trials. Stable HIV-1 prevalence can mask su bstantial incidence in a population with high turnover.